Skyrizi Psoriatic Arthritis Drug Insight And Market Forecast

“SKYRIZI Drug Insight and Market Forecast – 2032” report provides comprehensive insights about SKYRIZI for Psoriatic Arthritis (PsA) in the seven major markets. A detailed picture of the SKYRIZI for psoriatic arthritis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the SKYRIZI for psoriatic arthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SKYRIZI market forecast analysis for psoriatic arthritis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in psoriatic arthritis.

Drug Summary

SKYRIZI is an IL-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is linked to several chronic immune-mediated diseases, including psoriasis. SKYRIZI is approved in Japan for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and PsA in adults who have an inadequate response to conventional therapies.

SKYRIZI received US FDA approval and is used in the US to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, as well as to treat active PsA and Crohn’s disease in adults. The approved dose for SKYRIZI is 150 mg (one 150 mg pre-filled pen or pre-filled syringe) administered by SC injection at Weeks 0 and Week 4 and every 12 weeks thereafter.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SKYRIZI description, mechanism of action, dosage and administration, research and development activities in psoriatic arthritis.
• Elaborated details on SKYRIZI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SKYRIZI research and development activities in psoriatic arthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SKYRIZI.
• The report contains forecasted sales of for psoriatic arthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for psoriatic arthritis.
• The report also features the SWOT analysis with analyst views for SKYRIZI in psoriatic arthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SKYRIZI Analytical Perspective by DelveInsight

In-depth SKYRIZI Market Assessment

This report provides a detailed market assessment of SKYRIZI for psoriatic arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

SKYRIZI Clinical Assessment

The report provides the clinical trials information of SKYRIZI for psoriatic arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for psoriatic arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKYRIZI dominance.
• Other emerging products for psoriatic arthritis are expected to give tough market competition to SKYRIZI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKYRIZI in psoriatic arthritis.
• Our in-depth analysis of the forecasted sales data of SKYRIZI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SKYRIZI in psoriatic arthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of SKYRIZI?
• What is the clinical trial status of the study related to SKYRIZI in psoriatic arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKYRIZI development?
• What are the key designations that have been granted to SKYRIZI for psoriatic arthritis?
• What is the forecasted market scenario of SKYRIZI for psoriatic arthritis?
• What are the forecasted sales of SKYRIZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to SKYRIZI for psoriatic arthritis?
• Which are the late-stage emerging therapies under development for the treatment of psoriatic arthritis?